Evidence map›Paper›PMID 28785928›Full record

ArticleMolecular diversity2017

Molecular diversity of phenothiazines: design and synthesis of phenothiazine-dithiocarbamate hybrids as potential cell cycle blockers.

Dong-Jun Fu, Ruo-Han Zhao, Jia-Huan Li, Jia-Jia Yang, Ruo-Wang Mao, Bo-Wen Wu, Ping Li, Xiao-Lin Zi, Qing-Qing Zhang, Hui-Jie Cai and 3 more

Open access · greenAbstract read
In one paragraph

Article in Molecular diversity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Dong-Jun FuNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Ruo-Han ZhaoNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Jia-Huan LiNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Jia-Jia YangNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Ruo-Wang MaoNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Bo-Wen WuNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Ping LiNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Xiao-Lin ZiPathology and Laboratory Medicine, University of California, Irvine, Orange, CA, 92868, USA.
Qing-Qing ZhangNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Hui-Jie CaiNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Sai-Yang ZhangSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China. celeron16@163.com.
Yan-Bing ZhangNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. zhangyb@zzu.edu.cn.
Hong-Min LiuNew Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. liuhm@zzu.edu.cn.
Zhengzhou University · CNUniversity of California, Irvine · US

Funding

The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKAR01CA193967 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2016 to 2020
$1.8M
Chemoprevention of urinary bladder carcinogenesis by flavokawain AR01CA122558 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2008 to 2012
$1.7M
National Natural Sciences Foundations of China 81273393National Natural Sciences Foundations of China 81673322NCI NIH HHS R01 CA122558NCI NIH HHS R01 CA193967
6 · The paper itself

Abstract

Novel phenothiazine-dithiocarbamate analogues were designed by molecular hybridization strategy and synthesized and evaluated for their anticancer activity in vitro against three selected cancer cell lines (EC-109, MGC-803, and PC-3). The preliminary structure-activity relationship (SAR) for this phenothiazine-dithiocarbamate hybrids is explored. Among all analogues, 2-oxo-2-(10H-phenothiazin-10-yl)ethyl 4-ethylpiperazine-1-carbodithioate (8a) showed the most potent inhibitory activity with an [Formula: see text] value of [Formula: see text] against PC-3 cells. In addition, compound 8a could arrest the cell cycle at the G1 phase and regulate the expression of G1 checkpoint-related proteins, suggesting that phenothiazine-dithiocarbamate hybrids might be useful as cell cycle blockers.

Indexed as

Drug DesignAntineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationChemistry Techniques, SyntheticDrug Screening Assays, AntitumorHumansPhenothiazinesStructure-Activity RelationshipAntineoplastic AgentsPhenothiazinesAntiproliferative activityDithiocarbamateG1 checkpoint-related proteinG1 phasePhenothiazine

Identifiers

PMID28785928
PMCPMC5975273
OpenAlexW2742383574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.